Related Experiment Video
Updated: Mar 16, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.5K
TPH1 A218 allele is associated with suicidal behavior in Turkish population
Onur Beden1, Ender Senol1, Sevcan Atay2
1Ege University, School of Medicine, Department of Forensic Medicine, Bornova, Izmir 35100, Turkey.
Legal Medicine (Tokyo, Japan)
|August 7, 2016
Summary
The TPH1 A218C polymorphism
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Serotonergic dysfunction is linked to depression and suicidal behaviors.
- Tryptophan hydroxylase (TPH) enzyme, encoded by TPH1 and TPH2 genes, regulates serotonin synthesis.
- Genetic association studies on the TPH1 A218C polymorphism and suicidal behavior have yielded inconsistent results.
Purpose of the Study:
- To investigate the association between the TPH1 A218C (rs1800532) polymorphism and suicidal behavior in the Turkish population.
- To analyze genotype and allele frequencies of the TPH1 A218C polymorphism in suicide attempters and healthy controls.
Main Methods:
- Genotyping of the TPH1 A218C polymorphism using Real Time PCR in 109 suicide attempters and 98 healthy controls.
- Statistical analysis including Fisher's exact test and Pearson's chi-squared test for Hardy-Weinberg equilibrium.
- Collection of socio-demographic data via questionnaires.
Main Results:
- The A allele frequency was significantly higher in suicide attempters compared to controls (46.33% vs. 35.71%, p=0.0357).
- No significant differences in genotype frequencies were observed between suicide attempters and controls.
- In males, the CC genotype and C allele were more frequent in controls, while no significant associations were found in females.
Conclusions:
- The A allele of the TPH1 A218C polymorphism may be associated with suicidal behavior in the Turkish population.
- The findings suggest a potential genetic marker for suicidal behavior, particularly in males.
- Further research is warranted to confirm these associations in larger and diverse populations.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
57
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
95
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
95
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73